Acamprosate calcium
Acamprosate calcium structure
|
Common Name | Acamprosate calcium | ||
|---|---|---|---|---|
| CAS Number | 77337-73-6 | Molecular Weight | 200.24 | |
| Density | N/A | Boiling Point | N/A | |
| Molecular Formula | C5H10NO4S.1/2Ca | Melting Point | >300ºC | |
| MSDS | Chinese USA | Flash Point | N/A | |
| Symbol |
GHS07 |
Signal Word | Warning | |
|
Combining two repurposed drugs as a promising approach for Alzheimer's disease therapy.
Sci. Rep. 5 , 7608, (2015) Alzheimer disease (AD) represents a major medical problem where mono-therapeutic interventions demonstrated only a limited efficacy so far. We explored the possibility of developing a combinational therapy that might prevent the degradation of neuronal and en... |
|
|
Chronic treatment with novel brain-penetrating selective NOP receptor agonist MT-7716 reduces alcohol drinking and seeking in the rat.
Neuropsychopharmacology 39(11) , 2601-10, (2014) Since its discovery, the nociceptin/orphanin FQ (N/OFQ)-NOP receptor system has been extensively investigated as a promising target to treat alcoholism. Encouraging results obtained with the endogenous ligand N/OFQ stimulated research towards the development ... |
|
|
Acamprosate calcium as augmentation therapy for anxiety disorders.
Ann. Pharmacother. 44 , 1930-2, (2010) Glutamate is a major excitatory neurotransmitter, while γ-aminobutyric acid (GABA) is a predominant inhibitory neurotransmitter in the central nervous system. This GABA-glutamate imbalance is thought to play a role in the development of anxiety. Acamprosate c... |
|
|
Pharmacokinetics of acamprosate calcium in healthy Chinese subjects after oral administration of three dosage levels.
Arzneimittelforschung 59 , 631-4, (2009) To study the pharmacokinetics of acamprosate calcium (CAS 77337-73-6) in healthy Chinese subjects after oral administration of three dosage levels, 12 healthy subjects were divided into three groups and given a single oral dose of 333 or 666 or 1332 mg acampr... |
|
|
Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence Baser, O., et al.
Am. J. Manag. Care 8 , S222-34, (2011)
|